Piribedil
- Molecular formula
- C17H19F1N2O2
- CAS Number
- 3605-01-0
- IUPAC Name
- 8-[4-(4-fluorophenyl)-4-oxo-butyl]-2,4-dimethyl-2,8-diazaspiro[4.5]decane-1,3-dione
- Molecular Weight
- 317.38g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.2923g/cm3
- Synonyms
- UNII-475PMO19RG
Identification
Interesting Facts About 8-[4-(4-Fluorophenyl)-4-oxo-butyl]-2,4-dimethyl-2,8-diazaspiro[4.5]decane-1,3-dione
This intriguing compound, with a complex structure, belongs to a class of molecules known for their diverse applications in medicinal chemistry and drug development. Its unique arrangement of functional groups and spirocyclic structure contribute to its potential biological activities.
Key Characteristics:
- Structural Diversity: The compound features a spirocyclic framework, which can play a pivotal role in the overall properties and reactivity of the molecule.
- Fluorine Influence: The presence of a fluorine atom, specifically in the 4-fluorophenyl group, often enhances the lipophilicity and metabolic stability of the compound, making it a promising candidate for pharmaceutical applications.
- Biological Potential: Compounds with similar structures have been investigated for their ability to modulate biological pathways, suggesting that this compound could exhibit significant pharmacological properties.
Researchers are particularly interested in the use of spiro compounds in creating novel drugs. As noted by chemists, “The unique properties offered by spirocyclic systems often lead to improved bioactivity and selectivity” which makes this compound an exciting subject for further studies.
Moreover, the compound's diazabicyclic core could lend itself to various synthetic modifications, allowing scientists to explore analogs with different pharmacological profiles. This flexibility opens the door for potential innovation in drug design aimed at treating various conditions.
In summary, the exploration of this compound could yield significant advancements in our understanding of drug mechanisms and the development of new therapeutic agents.